Defining cancer risks for BRCA germline mutation carriers:: implications for surgical prophylaxis

被引：20

作者：

Karlan, BY

机构：

[1] Cedars Sinai Med Ctr, Dept Obstet & Gynecol, Womens Canc Res Inst, Los Angeles, CA 90048 USA

[2] Cedars Sinai Med Ctr, Div Gynecol Oncol, Los Angeles, CA 90048 USA

[3] Univ Calif Los Angeles, Geffen Sch Med, Los Angeles, CA USA

来源：

GYNECOLOGIC ONCOLOGY | 2004年 / 92卷 / 02期

关键词：

D O I：

10.1016/j.ygyno.2003.12.009

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：519 / 520

页数：2

共 16 条

[1]

Brose MS, 2002, J NATL CANCER I, V94, P1365, DOI 10.1093/jnci/94.18.1365

[2] Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 study [J].

Fisher, B ;

Costantino, JP ;

Wickerham, DL ;

Redmond, CK ;

Kavanah, M ;

Cronin, WM ;

Vogel, V ;

Robidoux, A ;

Dimitrov, N ;

Atkins, J ;

Daly, M ;

Wieand, S ;

Tan-Chiu, E ;

Ford, L ;

Wolmark, N .

JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1998, 90 (18) :1371-1388

[3] Sequence analysis of BRCA1 and BRCA2:: Correlation of mutations with family history and ovarian cancer risk [J].

Frank, TS ;

Manley, SA ;

Olopade, OI ;

Cummings, S ;

Garber, JE ;

Bernhardt, B ;

Antman, K ;

Russo, D ;

Wood, ME ;

Mullineau, L ;

Isaacs, C ;

Peshkin, B ;

Buys, S ;

Venne, V ;

Rowley, PT ;

Loader, S ;

Offit, K ;

Robson, M ;

Hampel, H ;

Brener, D ;

Winer, EP ;

Clark, S ;

Weber, B ;

Strong, LC ;

Rieger, P ;

McClure, M ;

Ward, BE ;

Shattuck-Eidens, D ;

Oliphant, A ;

Skolnick, MH ;

Thomas, A .

JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (07) :2417-2425

[4]

Goldman NA, 2002, ASCO P, V21, p221a

[5] Is uterine papillary serous adenocarcinoma a manifestation of the hereditary breast-ovarian cancer syndrome? [J].

Goshen, R ;

Chu, W ;

Elit, L ;

Pal, T ;

Hakimi, J ;

Ackerman, I ;

Fyles, A ;

Mitchell, M ;

Narod, SA .

GYNECOLOGIC ONCOLOGY, 2000, 79 (03) :477-481

[6] HORMONE REPLACEMENT THERAPY AND ENDOMETRIAL CANCER RISK - A METAANALYSIS [J].

GRADY, D ;

GEBRETSADIK, T ;

KERLIKOWSKE, K ;

ERNSTER, V ;

PETITTI, D .

OBSTETRICS AND GYNECOLOGY, 1995, 85 (02) :304-313

[7]

Grann VR, 2002, J CLIN ONCOL, V20, P2520, DOI 10.1200/JCO.2002.10.101

[8] Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. [J].

Kauff, ND ;

Satagopan, JM ;

Robson, ME ;

Scheuer, L ;

Hensley, M ;

Hudis, CA ;

Ellis, NA ;

Boyd, J ;

Borgen, PI ;

Barakat, RR ;

Norton, L ;

Offit, K .

NEW ENGLAND JOURNAL OF MEDICINE, 2002, 346 (21) :1609-1615

[9] Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2 -: National Surgical Adjuvant Breast and Bowel Project (NSABP-P1) Breast Cancer Prevention Trial [J].

King, MC ;

Wieand, S ;

Hale, K ;

Lee, M ;

Walsh, T ;

Owens, K ;

Tait, J ;

Ford, L ;

Dunn, BK ;

Costantino, J ;

Wickerham, L ;

Wolmark, N ;

Fisher, B .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 286 (18) :2251-2256

[10] Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2 [J].

King, MC ;

Marks, JH ;

Mandell, JB .

SCIENCE, 2003, 302 (5645) :643-646

← 1 2 →